Bill Anderson

- Member of the Board of Management of Bayer AG since April 1, 2023; Chairman of the Board of Management (CEO) of Bayer AG since June 1, 2023 - Bachelor of Science degree from the University of Texas and a Master of Science degree from the Massachusetts Institute of Technology (MIT), both in Chemical Engineering; a Master of Science in Management from MIT’s Sloan School - Started professional career in 1989 at Ethyl Corporation, a U.S. -based specialty chemical company, with postings in Belgium and the Netherlands - In 1995 joined Raychem Corporation, a U.S.-based material science and electronics firm - In 1997, moved to Biogen, an American biotechnology firm, as a finance manager, then became GM of the UK affiliate and eventually Vice President of Biogen’s Neurology Unit - In 2006 joined Genentech, a pioneering biotechnology company, eventually serving as Senior Vice President of the firm’s oncology business - In 2013, joined Roche Pharmaceuticals, the parent company of Genentech, as Head of Global Product Strategy and Chief Marketing Officer - In 2016, moved back to Genentech to assume the position of Head of North American Operations before becoming CEO of the company in 2017 - In 2019, became CEO of Roche Pharmaceuticals based in Switzerland